Related Experiment Video
Updated: Jan 15, 2026

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid: Successful Treatment with Dupilumab while Maintaining
Cristina-Maria Florea1, Laurent Parmentier2, Mohamed Abdou2,3
1Department of Medical Oncology, Sion Hospital, Sion, Switzerland.
Introduction:
Immune checkpoint inhibitors (ICIs) represent a new class of antitumor agents in oncology. Their use has been associated with a specific safety profile, known as immune-related adverse events (irAEs), with dermatological toxicities being the most frequently encountered.
Case Report:
We report the case of a bullous pemphigoid (BP) in a metastatic melanoma patient, treated with ipilimumab and nivolumab. This immune-mediated toxicity was controlled by using dupilumab as a steroid-sparing therapy, allowing the reintroduction of immunotherapy without relapse.
Conclusion:
This case illustrates the complexity of managing some dermatological irAEs and the need for better treatment strategies. Dupilumab is a promising agent for cutaneous irAEs, including ICI-BP. To our knowledge, our case is the first one in which a rechallenge with an ICI was attempted after a dupilumab treatment for an ICI-BP.
Related Concept Videos
Tumor Immunotherapy
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

